{"prompt": "['Boehringer', 'Ingelheim', 'Clinical Trial Protocol', 'Document Number:', 'c19558808-06', 'EudraCT No.:', 'Not applicable.', 'EU Trial No:', 'BI Trial No.:', '1199-0324', 'BI Investigational', 'Nintedanib', 'Product(s):', 'Title:', 'Study of Pulmonary Rehabilitation In Nintedanib Treated', 'Patients with IPF: Improvements in Activity, Exercise', 'Endurance Time, and QoL', 'Lay Title:', 'Study of pulmonary rehabilitation in patients with Idiopathic', 'Pulmonary Fibrosis (IPF)', 'Clinical Phase:', 'IV', 'Clinical Trial', 'Leader:', 'Coordinating', 'Investigator:', 'Status:', 'Final Protocol (Revised Protocol based on Global Amendment', '2)', 'Version and Date:', 'Version: 3.0', 'Date: 16 Dec 2019', 'Page 1 of 103', 'Proprietary confidential information.', '\u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved.', 'This document may not - in full or in part - be passed on, reproduced, published or otherwise used without prior written permission']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 2 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'CLINICAL TRIAL PROTOCOL SYNOPSIS', 'Company name', 'Boehringer Ingelheim', 'Finished product name', 'OFEV', 'Active ingredient', 'Nintedanib', 'name:', 'Protocol date', '15 Aug 2018', 'Revision date', '16 Dec 2019', 'Trial number', '1199-0324', 'Title of trial:', 'Study of Pulmonary Rehabilitation In Nintedanib Treated Patients', 'with IPF: Improvements in Activity, Exercise Endurance Time, and', 'QoL', 'Coordinating', 'Investigator:', 'Trial site(s):', 'Multicenter', 'Clinical phase:', 'IV', 'Objective(s):', 'Determine the difference in change from baseline in 6MWD when', 'pulmonary rehabilitation (PR) is added to stable underlying', 'nintedanib therapy in patients with idiopathic pulmonary fibrosis', '(IPF)', 'Determine the difference in change in Quality of Life (QoL) when', 'pulmonary rehabilitation (PR) is added to stable underlying', 'nintedanib therapy in patients with idiopathic pulmonary fibrosis', '(IPF)', 'Determine if there is an enduring effect in 6MWD, QoL and lung', 'function from pulmonary rehabilitation (PR) when pulmonary', 'rehabilitation (PR) is added to stable underlying nintedanib therapy', 'in patients with idiopathic pulmonary fibrosis (IPF)', 'Methodology:', 'Multi-centre, prospective, randomised, open label clinical trial', 'Number of patients', 'entered:', '290 (96 sub-study)', 'Number of patients on', 'each treatment:', '145 (48 sub-study)', 'Diagnosis:', 'Idiopathic Pulmonary Fibrosis (IPF) according to American', 'Thoracic Society (ATS), European Respiratory Society (ERS),', 'Japanese Respiratory Society (JRS), and Latin American Thoracic', 'Association (ALAT) criteria published in 2011, consistent with', 'INPULSIS criteria Inclusion', 'Main in- and exclusion', 'Age > 40 years.', 'criteria', 'Forced Vital Capacity (FVC) > 45% of predicted', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 3 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'FEV1/FVC greater than/equal to .7 and Carbon Monoxide', 'Diffusion Capacity (DLco) (corrected for hemoglobin [Hgb])', '30-79% of predicted', 'Confirmed diagnosis of IPF according to 2011', 'ATS/ERS/JRS/ALAT guidelines by High Resolution Computed', 'Tomography (HRCT) (consistent with INPULSIS criteria) or', 'lung biopsy taken within 24 months prior to providing', 'Informed Consent', 'Treated on a stable dose of nintedanib for up to 30 months.', 'Patients who have recently started nintedanib 150 mg BID and', 'have started by the day of randomization must be on nintedanib', '150 mg BID a minimum of 10 days by the first day of', 'pulmonary rehabilitation.', 'Exclusion', 'Major surgery within 12 weeks prior to randomization or', 'planned within 6 months after screening which could interfere', 'with the ability to participate in pulmonary rehabilitation', 'Active or suspected malignancy or history of malignancy within', '3 years prior to screening', 'Currently enrolled in or less than 30 days since ending another', 'interventional investigational device or drug trial', 'Women who are pregnant, nursing, or who plan to become', 'pregnant in the trial', 'Previous participation in pulmonary rehabilitation program', 'within 45 days prior to signing informed consent', 'Test product(s):', 'nintedanib', 'dose:', '150 mg BID', 'mode of', 'oral', 'administration:', 'Comparator products:', 'None', 'dose:', 'NA', 'mode of', 'NA', 'administration:', 'Duration of treatment:', '24 weeks', 'Endpoints', 'Primary Endpoint', 'Change from baseline in 6MWD at 12 weeks', 'Secondary Endpoints', 'Change from baseline in QoL (SGRQ, KBILD, UCSD', 'SOBQ) at 12 and 24 weeks', 'Change from baseline in 6MWD at 24 weeks', 'Change from baseline in lung function (FVC) at 12 weeks', 'and 24 weeks using each of', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}